This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The FDA has announced several guidelines and plans to hold at least one public meeting on digitalhealthtechnologies (DHTs) to be used in drug clinical trials by the end of the year. Drugdevelopment process questions the reliability and accuracy of DHT products.
DigitalHealthTechnologies ( DHTs ) have revolutionized the landscape of clinical trials, particularly in neurology research, by enabling the collection of real-world data outside traditional clinical settings.
BASEL, Switzerland–(BUSINESS WIRE)–Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digitalhealthtechnology and developdigital biomarkers for Parkinson’s disease.
Koneksa’s innovative digital model aims to address limitations in existing functional status assessments by leveraging digitalhealthtechnologies (DHTs) for both objective and self-reported outcomes. Chief Medical Officer, Koneksa. Chief Scientific Officer, Koneksa.
NEW YORK–(BUSINESS WIRE)– Deliberate AI , a digitalhealthtechnology company that delivers precision measurement of mental health through AI, today announced its inclusion in the U.S. Food and Drug Administration (FDA) Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program.
Despite a history of drugdevelopment failures in the field, recent work provides reason for optimism, showing a possible therapeutic arsenal to limit disease progression at an early stage.
In this scenario, a patient can digitally determine who should have access to the medical record (and which portion), which person(s) or entities saw or modified the record (and what portion) and when. Herding a patient’s data from many sources into a single record has always been a lofty goal of digitalhealth.
Digitalhealthtechnologies (DHT) can collect objective, multi-dimensional data passively and remotely with a limited burden for clinical trial participants, providing a way to capture previously inaccessible insights to support drugdevelopment and commercialization.
This patient-centric approach ensures that new treatments are not only effective but that they improve quality of life, enhance adherence to therapy, and ultimately achieve better health outcomes.
–(BUSINESS WIRE)–AstraZeneca today launches Evinova, set to be a leading provider of digitalhealth solutions to better meet the needs of healthcare professionals, regulators and patients. in 2060.
The investment adds to a growing list of prominent digitalhealth investors in Europe and the United States, including Nina Capital and Young Sohn, a co-founder of Veeva Systems. The funding speaks to the global nature of pre-approval access and its increasing importance in the drugdevelopment process. “
This pilot study represents a critical step in leveraging digitalhealthtechnology to enhance cancer treatment outcomes,” said John Wagner, M.D., The study, led by principal investigator Nitin Ohri, M.D., Chief Medical Officer, Koneksa. “By
Furthermore, the industry witnessed a decline in the average return on investment (ROI) for R&D to as low as 1.2%, and the peak sales per asset valued just above $350 million, indicating a need to build more efficient drugdevelopment processes with the implementation of newer technologies.
“The utilization of evidence-based digital biomarkers is the key to transforming healthcare,” said Chris Benko, CEO, Koneksa. “We’re We’re on a mission to revolutionize drugdevelopment in clinical trials by harnessing the power of our digital solutions with real-time, data-driven insights.
Exec Summary: DigitalHealth is a subset of Healthtech. DigitalHealth focuses on the individual patient, while Healthtech focuses on the entire healthcare ecosystem. Artificial intelligence: This is a rapidly developing field that has the potential to revolutionize healthcare. Subscribe Today!
The increasing importance of digitalhealth, coupled with abundant capital and supportive regulatory environments, is likely to drive continued M&A activity and higher valuations. Regulatory Environment: Favourable regulatory policies and increased government support for digitalhealth initiatives are fostering innovation.
Exec Summary: The HealthTech sector is poised for significant M&A activity in 2025, driven by several key trends: DigitalHealth Solutions: The increasing demand for digitalhealth solutions to improve healthcare accessibility and efficiency will drive acquisitions of innovative startups and established players in this space.
When it comes to incorporating new technology into drugdevelopment and clinical practice, the best place to start is with the patients. Each article opens with an actual clinical case where wearable data was used to care for a patient.
In the context of healthtech and digitalhealth, it means a company initially targets consumers (B2C), builds a strong user base, and then leverages this consumer adoption to attract businesses (B2B), such as insurers, employers, or healthcare providers. Exec Summary: B2C2B stands for Business-to-Consumer-to-Business.
Whether it is in operational delivery, service provision, patient enablement or drug discovery, technology has continued to create wide scale impact as we shift towards a post-pandemic world. In fact, Exscientia stands by the claim that all drugs in the future will be made using AI. .
With access to these collective resources and by capitalizing on existing biosamples as well as clinical data, including that from digitalhealthtechnology, researchers will focus on identifying and validating biomarkers and therapeutic targets specific to ALS.
Elevating Global Patient Access to Clinical Trials through Revolutionary Collaboration and Advanced AI-Driven Technologies NEW YORK–(BUSINESS WIRE)– Massive Bio Inc.,
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content